Want to see JP:4934 full AI Analyst Report?
Top Page
Premier Anti-Aging Co., Ltd.
(4934)
Select Model
Select Model
Rating:50Neutral
Price Target:
¥600.00
▼(-4.00% Downside)
Action:Reiterated
Date:08/06/26
Overall score is held back primarily by bearish technicals (trading below major moving averages with negative MACD and low RSI). Financial performance is mixed—strong gross margin and a conservative balance sheet are positives, but declining revenue and low net margin limit the fundamental score. Valuation is neutral at a P/E of 21.16, with no dividend data available to improve the assessment.
Positive Factors
High Gross Margin
A 76.65% gross margin indicates durable product-level profitability and likely pricing power or low COGS. This high margin provides long-term buffer to absorb SG&A and supports reinvestment in products, marketing, or R&D even if top-line growth is uneven.
Negative Factors
Declining Revenue
Sustained revenue decline (-7.23%) signals weakening demand or competitive pressure in core product and service lines. Over several months this erodes scale economics, limits ability to invest for growth, and makes margin expansion harder despite high gross margins.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A 76.65% gross margin indicates durable product-level profitability and likely pricing power or low COGS. This high margin provides long-term buffer to absorb SG&A and supports reinvestment in products, marketing, or R&D even if top-line growth is uneven.
Read all positive factors
Premier Anti-Aging Co., Ltd. (4934) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.22B
Dividend YieldN/A
Average Volume (3M)11.01K
Price to Earnings (P/E)20.7
Beta (1Y)0.71
Revenue Growth-18.19%
EPS Growth-65.57%
CountryJP
Employees216
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)28.78
Shares Outstanding8,720,534
10 Day Avg. Volume8,960
30 Day Avg. Volume11,006
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.14
Price to Sales (P/S)0.47
P/FCF Ratio5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.1
Revenue Forecast (FY)¥14.60B
Premier Anti-Aging Co., Ltd. Business Overview & Revenue Model
Company Description
Premier Anti-Aging Co., Ltd. engages in the planning, development, import, export, mail order/EC, wholesale, and retail of cosmetics, health foods, and recovery wear in Japan. The company is involved in anti-aging and recovery businesses; and manu...
How the Company Makes Money
Premier Anti-Aging Co., Ltd. generates revenue primarily by selling its anti-aging-related products and services. Key revenue streams are expected to include (1) product sales to consumers (e.g., via direct-to-consumer channels such as online sale...
Premier Anti-Aging Co., Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.25B | 16.16B | 20.36B | 26.40B | 33.91B | 32.81B |
| Gross Profit | 10.76B | 12.39B | 16.10B | 19.24B | 26.63B | 26.43B |
| EBITDA | 395.00M | 916.00M | 390.00M | -423.24M | 2.50B | 4.72B |
| Net Income | 251.00M | 471.00M | -1.48B | -733.97M | 1.42B | 2.79B |
Balance Sheet | ||||||
| Total Assets | 10.47B | 10.14B | 11.05B | 12.18B | 12.30B | 13.07B |
| Cash, Cash Equivalents and Short-Term Investments | 4.84B | 4.66B | 4.76B | 4.67B | 2.97B | 6.06B |
| Total Debt | 1.24B | 1.11B | 2.44B | 2.26B | 1.41B | 911.41M |
| Total Liabilities | 3.34B | 3.53B | 4.92B | 4.57B | 3.95B | 6.17B |
| Stockholders Equity | 7.13B | 6.61B | 6.12B | 7.61B | 8.35B | 6.90B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.44B | -204.00M | 2.40B | -3.35B | 2.75B |
| Operating Cash Flow | 0.00 | 1.47B | 425.00M | 2.42B | -3.32B | 2.75B |
| Investing Cash Flow | 0.00 | -229.00M | -540.00M | -900.97M | -297.68M | -180.83M |
| Financing Cash Flow | 0.00 | -1.34B | 183.00M | 179.77M | 501.62M | 1.58B |
Premier Anti-Aging Co., Ltd. Technical Analysis
Negative
625.00
Price Trends
609.12
Negative
610.37
Negative
656.91
Negative
Market Momentum
-4.60
Negative
42.12
Neutral
86.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4934, the sentiment is Negative. The current price of 625 is above the 20-day moving average (MA) of 599.60, above the 50-day MA of 609.12, and below the 200-day MA of 656.91, indicating a bearish trend. The MACD of -4.60 indicates Negative momentum. The RSI at 42.12 is Neutral, neither overbought nor oversold. The STOCH value of 86.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4934.
Premier Anti-Aging Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥1.71B | 8.80 | ― | ― | -6.17% | -55.84% | |
74 Outperform | ¥6.52B | 9.60 | ― | 2.29% | 0.16% | 6.35% | |
70 Outperform | ¥26.97B | 11.78 | ― | 0.91% | 13.71% | -16.12% | |
65 Neutral | ¥5.35B | 29.17 | ― | 1.68% | 3.17% | -27.27% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
58 Neutral | ¥7.86B | 43.28 | ― | 2.82% | 0.96% | -28.27% | |
50 Neutral | ¥5.22B | 20.74 | ― | ― | -18.19% | -65.57% |
* Consumer Defensive Sector Average
JP:4934
Premier Anti-Aging Co., Ltd.
597.00
-305.00
-33.81%
JP:4918
Ivy Cosmetics Corporation
300.00
0.34
0.11%
JP:4925
HABA Laboratories, Inc.
1,727.00
29.58
1.74%
JP:4926
C'BON COSMETICS Co., Ltd.
1,250.00
75.62
6.44%
JP:4933
I-ne CO., LTD.
1,481.00
-118.20
-7.39%
JP:4936
AXXZIA, Inc.
325.00
-105.25
-24.46%
Premier Anti-Aging Co., Ltd. Corporate Events
Premier Anti-Aging Restructures China Operations, Shuts Shanghai Subsidiary
Jul 17, 2026
Premier Anti-Aging Co., Ltd. has decided to dissolve and liquidate its consolidated subsidiary Premier Anti-Aging (Shanghai) Co., Ltd. as part of a structural reform of its China operations. The move reflects a strategic shift in how the company m...
Premier Anti-Aging to Liquidate Loss-Making China Subsidiary and Pivot to Cross-Border E-Commerce
Jul 14, 2026
Premier Anti-Aging Co., Ltd. has resolved to dissolve and liquidate its wholly owned Chinese subsidiary, Premier Anti-Aging (Shanghai) Co., Ltd., as part of a structural reform of its operations in China. The Shanghai unit, established in 2021 to ...
Premier Anti-Aging Cuts Sales Outlook but Maintains Profit Targets on Cost Reforms
Jun 12, 2026
Premier Anti-Aging Co., Ltd. has revised down its full-year net sales forecast for the fiscal year ending July 31, 2026 to ¥13.5 billion from ¥16.5 billion, while keeping operating, ordinary and net profit projections unchanged at ¥...
Premier Anti-Aging outlines FY2026 Q3 results and maintains full-year outlook
Jun 12, 2026
Premier Anti-Aging Co., Ltd. released its results briefing materials for the third quarter of FY2026, outlining performance and developments across its core operations. The company reported on its anti-aging and recovery business segments, reviewe...
Premier Anti-Aging Cuts Outlook as Nine-Month Profit Slides
Jun 12, 2026
Premier Anti-Aging reported consolidated net sales of ¥10.59 billion for the first nine months of the fiscal year ending July 31, 2026, down 15.3% year on year, with operating profit falling 41.4% to ¥742 million and profit attributable ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.